Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taris Biomedical, a specialty pharmaceutical company focused into the field of drug-device convergence for targeted therapies, has appointed Sarma Duddu, as president and CEO and a member of the board of directors of the company, effective immediately.
Subscribe to our email newsletter
Most recently, Dr Duddu held the position of general manager and vice president of worldwide drug delivery technologies of Cima Labs, a wholly owned subsidiary of Cephalon.
Prior to Cephalon, Dr Duddu has served as vice president of pharmaceutical development at Nektar Therapeutics, a drug delivery company based in San Carlos.
Dr Duddu said: “Taris has truly novel drug-device convergence product candidates in therapeutic areas with high unmet medical need, and I am excited to accept this opportunity to take Taris to the next stage of its development.”
Michael Cima, co-founder and consultant to the Taris Biomedical management team, said: “We are extremely pleased that Sarma Duddu has joined Taris as the CEO. Sarma is a accomplished drug developer with significant expertise in drug delivery and is ideally suited to lead the company as it develops its products for genitourinary indications.”